Bicyclic Heterocyclic p-38 Kinase Inhibitors

A compound that has formula I:

• or a pharmaceutically acceptable derivative thereof, wherein:
• R1 is alkyl,
• R2 at each occurrence is independently selected from alkyl, or cycloalkyl,
• n is 0, 1 or 2;
• R3 is cycloalkyl;
• Y is —C(═O)NH—, or —SO2NH—,
• X1 is a single bond, or alkylene;
• A is imidazolopyrimidine or imidazolopyrimidinone and is optionally substituted with up to two R13;
• X2 is a single bond, alkylene, —NH—, —N(C1-4alkyl)-, —NH—C1-4alkylene-, —N(C1-4alkyl)-C1-4 alkylene;
• D is a monocyclic or bicyclic aromatic or non-aromatic ring system optionally containing up to four heteroatoms selected from N, O, and S, or D is C1-6alkyl, and wherein D is optionally substituted by one to four (CR9R10)wE groups;
• CR9R10)wE is alkyl, alkoxy, halo, —CH2-heterocyclyl, —CONH-cycloalkyl, alkylsulfonyl, alkylthio, alkylsulfonylamino, haloalkyl, aminocarbonyl, alkylcarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, heterocyclylalkyl, alkylcarbonyl-N(alkyl)-, cycloalkylaminocarbonyl, alkylaminocarbonyl, heteroaryl, dialkylaminoalkyl, pseudohalo or heterocyclyl, or two (CR9R10)wE groups, which substitute adjacent atoms on D, together form alkylenedioxy;
• R13 is hydrogen, alkyl hydroxy or NH2.